|
![]() |
EscitalopramThis page contains recent news articles, when available, and an overview of Escitalopram but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Escitalopram (when available) Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase. For the treatment of major depressive disorder and Generalized Anxiety Disorder (GAD). Mechanism Of Action: The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. News Articles on Escitalopram Australia: Enantiomer Patent Valid In Australia; Extension Of Term ... - Aug 17, 2009 The case relates to Lundbeck's patent for escitalopram, the (+)-enantiomer of citalopram, a pharmaceutical used in the treatment of depression. Mondaq News Alerts (registration) PRESS RELEASE: Second Quarter 2009 Report - Lundbeck Records 18 ... - Aug 12, 2009 ...(escitalopram) for the treatment of depression and anxiety rose to DKK 1345 million, an increase of 9%. Lexapro?? revenue, escitalopram marketed in the US Wall Street Journal Lexapro Litigation Settled With Brand Companies - Aug 3, 2009 Forest and Lundbeck will give Caraco licenses to market its version of Lexapro (escitalopram oxalate) when other generic companies start doing so. FDA news (subscription) Antidepressant suicide risk varies by age -US FDA - Aug 11, 2009 N) Celexa, or citalopram, and Lexapro, or escitalopram, "seem to increase the risk of suicidal events," Geddes and colleagues wrote. Reuters Drug shortages affecting patients, new survey finds - Aug 27, 2009 Pharmacists described how one patient had panic attacks while waiting for the antidepressant Cipralex (escitalopram), another experienced rising blood Pharma Times Second quarter 2009 report - Lundbeck records 18% revenue growth ... - Aug 14, 2009 Revenue from Cipralex® (escitalopram) for the treatment of depression and anxiety rose to DKK 1345 million, an increase of 9%. PharmaLive.com (press release) Doctors Often Unaware of Drugs' Approval Status - Aug 21, 2009 ...escitalopram (Lexapro) for panic disorder; gabapentin for diabetic neuropathy; trazodone for insomnia; venlafaxine (Effexor) for adjustment disorder; MedPage Today Life Sciences Update - 28 August 2009 - Aug 28, 2009 623144 of H Lundbeck A/S for the enantiomer escitalopram. • The Full Court upheld the decision of the primary judge that the patent was novel but that the Linex Legal (registration) Best Practices for Treating Obsessive-Compulsive Disorder in ... - Aug 24, 2009 ...exposure and response prevention, or pharmacotherapy with an SSRI, such as citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline. Medscape Nycomed Deal Gets Forest New Shot at COPD Market - Aug 10, 2009 ...giving Forest a potential blockbuster drug just in time to start offsetting declining sales of big-seller antidepressant Lexapro (escitalopram oxalate), BioWorld Online All change please - unique considerations affecting biotech products - Aug 25, 2009 ...considered whether or not the resolved enantiomer of escitalopram and diastereomer of levofloxacin were novel and inventive over the racemic mixture. Linex Legal (subscription) Suicide risk with anti-depressants depends on age - Aug 18, 2009 ...(trade names Zoloft and Lustral) and escitalopram (trade names Lexapro and Cipralex) 'have the best balance of short term efficacy and tolerability'. malehealth Methods: The AGENDA trial is designed as a participant ... - Aug 11, 2009 Participants are randomized to escitalopram 10 mg per day versus placebo for fourweeks. Randomization is stratified by gender and age. 7thSpace Interactive (press release) [ì‹ ì œí’ˆ] ëª…ë¬¸ì œì•½, 효과 ë¹ ë¥¸ í•ìš°ìš¸ì œ 'ì—?ìŠ¤í† ëžŒì •' - Aug 23, 2009 ...ì—?ìŠ¤í† ëžŒì •ì?˜ 성분ì?€ ì—?스시탈로프람(escitalopram)ì?´ë‹¤. 시탈로프람ì?˜ 활성 ì?´ì„±ì§ˆì²´ì?¸ S-ì²´ë§Œ 분리한 ì œí’ˆìœ¼ë¡œ 기존 í•ìš°ìš¸ì œì™€ëŠ” 차별화ë?˜ëŠ” ì„¸ë¡œí† ë‹Œ 2중작용ì?„ 쿠키뉴스 Företag fällt för felaktig SSRI-annons - Aug 7, 2009 Lundbeck har fällts av Läkemedelsindustrins Informationsgranskningsman, IGM, för sin marknadsföring av det antidepressiva läkemedlet Cipralex (escitalopram) Janus í?¬ë ˆìŠ¤íŠ¸, 최초 COPD ì‹ ì•½ '닥사스' ë¯¸êµ ë‚´ 시íŒ? - Aug 14, 2009 ...í?¬ë ˆìŠ¤íŠ¸ëŠ” 약 2700명ì?˜ ì˜?업사ì›?ì?„ ë‘?ê³ ë¯¸êµë‚´ 시장ì—?서 활발한 ì˜?ì—…ì?„ í•˜ê³ ìžˆê³ ë?´ë§ˆí?¬ 룬드벡ì—?서 ê¸°ìˆ ì œíœ´ 한 í•ìš°ìš¸ì œ ë ‰ì‚¬í”„ë¡œ(Lexapro: escitalopram)를 ì?¸ê¸° 메디포뉴스 Forest与奈科明ç¾ç½²å?ˆä½œé”€å”®å??è®® 推广新è?¯Daxas - Aug 12, 2009 ...迄今为æ¢ï¼ŒForest销é‡?最大的产å“?为抗抑éƒ?剂Lexapro (escitalopram),它从丹麦Lundbeckå…¬å?¸èŽ·å¾—äº†è¿™ç§?è?¯ç‰©çš„ç»?销æ?ƒï¼Œä½†è¯¥è?¯çš„专利将于未æ?¥å‡ å¹´å?Žå¤±æ•ˆã€‚ 生物谷 Stragi famigliari, suicidi, sparatorie nelle scuole: cosa si ... - Aug 26, 2009 ...del Prodotto e Foglio Illustrativo) dei prodotti che contengono citalopram, escitalopram, fluoxetina, fluvoxamina, mianserina, minlacipran, mitrazapina, ECPlanet Ante el dolor de los neuróticos globales - Aug 22, 2009 Cuatro de los fármacos que tomaba eran para problemas psiquiátricos: clonazepam para la ansiedad, escitalopram para la depresión, oxacarbazepina para la Clarín.com å…¨ç?ƒåŒ»è?¯å¸‚场:å?‘下的曲线 ç–²æ€?下å¥?å“?强音 - Aug 26, 2009 ...这些产å“?分别是百时美施贵å®?çš„Abilify(aripiprazole);æ¦ç”°çš„Actos(pioglitzone);安进的Epogen (epoetin alfa);Forest Laboratoriesçš„Lexapro(escitalopram) 中国生物技术信息网 Perkembangan Terbaru Pengobatan Gangguan Depresi - Aug 25, 2009 Antiprestin), Sertraline (merk dagang: Serlof, Zoloft, Antipres) dan Escitalopram (merk dagang: Cipralex). Pengobatan depresi membutuhkan waktu. Kabar Indonesia Sun Pharma Rises Most in 3 Weeks on Suit Settlement - 13 Jul 2009 Industries Ltd. failed in its effort to invalidate one of the patents, which expires in 2012 and covers the drug's main compound, escitalopram. Bloomberg Sun Pharma enters pact with Forest Labs,H Lundbeck for Lexapro - Jul 10, 2009 According to the agreements, Sun would licence to Lundbeck certain patent applications related to the synthesis of escitalopram and citalopram in exchange Economic Times IP Alert: June 2009 - Jul 6, 2009 On the issue of the extension of the patent term, Lindgren J held that citalopram “containsâ€? escitalopram, since citalopram is a racemic mixture comprising Linex Legal (subscription) JAMA Softens Gag Rule - Jul 7, 2009 ...the lead author of a study evaluating the use of Lexapro (escitalopram) for poststroke depression, had failed to disclose his serving on the speakers GoozNew Lundbeck V Alphapharm - Jun 30, 2009 In a much anticipated decision the Full Federal Court has upheld the validity of Lundbeck's escitalopram patent for its 20 year term but would not allow an Mondaq News Alerts (registration) Moderation of antidepressant response by the serotonin transporter ... - Jun 30, 2009 Lundbeck provided both nortriptyline and escitalopram free of charge for the GENDEP study. GlaxoSmithKline contributed by funding an add-on project in the British Journal of Psychiatry PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts ... - Jul 10, 2009 Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation DETROIT, Trading Markets (press release) Australian Patent Office Clarifies Novelty Test For Enantiomers - Jun 24, 2009 623144 for the antidepressant drug escitalopram. The Full Court upheld the earlier judge's holding that the patent is valid and infringed but also upheld Patent Baristas Nifty breaks 3950 on weak Asian cues; realty, infra slip - Jul 12, 2009 However, Sun Pharma gained 2%, as the company was in pact with Forest Lab to settle Escitalopram dispute. Infosys was up 1.5% on the good quarterly earnings Moneycontrol.com BUY CHEAP IMITREX ONLINE - Jul 12, 2009 Before using Imitrex, tell your doctor if you are also taking an antidepressant such as citalopram (Celexa), duloxetine (Cymbalta), escitalopram (Lexapro), Cleveland Indy Media Intellectual Property News - Jul 2, 2009 ...confirms no extension of Lundbeck's Escitalopram patent / Federal Court grants interlocutory injunction in Sigma Pharmaceuticals and Wyeth patent case. Linex Legal (subscription) In the news: - Jul 9, 2009 ...the lead author of a study evaluating the use of Lexapro (escitalopram) for poststroke depression, had failed to disclose his serving on the speakers GoozNew Grief and Depression: Treatment Decisions for Bereaved Children ... - Jul 1, 2009 J Clin Psychiatry 2001; 62:227–230[Medline] Hensley PL, Slonimski CK, Uhlenhuth EH, Clayton PJ: Escitalopram: an open-label study of bereavement-related Am J Psychiatry (subscription) Cipla Medpro to focus on local market - Jul 6, 2009 Triomune, to last year's generic escitalopram depressant, Lexamil.â€? The company had also recently launched an anti-flu medication, Cipla Oseltamivir, Business Day ASCO Updates - Jun 18, 2009 Patients taking the so-called weaker antidepressants, Celexa (citalopram), Lexapro (escitalopram), and Luvox (fluvoxamine), did not have an increased risk Curetoday.com (press release) April - May - June Articles - Jun 29, 2009 ...in the ARTG was held to be the relevant first date of ARTG listing of the purified enantiomer (escitalopram) for assessment of eligibility for an EOT. Linex Legal (subscription) Phobias: When fear takes over - Jun 25, 2009 These include paroxetine (Paxil), citalopram (Celexa) and escitalopram (Lexapro). Children, teens and adults being treated with antidepressants, Kansas CW El prozac interfiere en la quimioterapia. - Jun 23, 2009 Los antidepresivos más "seguros" desde este punto de vista son, entonces, el citalopram, el escitalopram y la fluvoxamina. La Gaceta Tucumán How Big Pharma Distorts Science to Get FDA Approval for Dangerous ... - 20 Apr 2009 Last May a pro Lexapro article, "Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression," ran in JAMA, the Journal of the American AlterNet Forest Under Fire - Apr 8, 2009 Forest was also accused of using “illegalâ€? inducements to physicians to get them to prescribe citalopram and escitalopram. “By knowingly and actively Psychiatric Times Rationale, design and methodology of a double-blind, randomized ... - Apr 7, 2009 Methods: Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year. 7thSpace Interactive (press release) Treating the human condition - Apr 14, 2009 When one Googles "Escitalopram" (the generic name of Cypralex, which is marketed in the US as Lexapro), over 1 million hits come up. Ha'aretz Cognitive Behavior Therapy Eases Anxiety for Older People - Apr 7, 2009 Another study, however, confirmed that Lexapro (escitalopram) was an effective anxiety treatment. This study, published in the Jan. Forbes Groundbreaking study into depression - Apr 16, 2009 ...brain and cognitive markers that can predict specific responses to a range of antidepressants including sertraline, escitalopram and venlafaxine. The Virtual Medical Centre JAMA editors embroiled in brouhaha over treatment of critic - Apr 1, 2009 ...in the May 2008 issue of JAMA touting the supposed benefits of the antidepressant Lexapro (escitalopram) in warding off the blues in stroke victims. Scientific American Prevention of first-episode depression: progress and potential - Mar 31, 2009 5 Escitalopram-treated patients (n=59) (10 mg/day, age <65 and 5 mg/day, age 65) were significantly less likely to develop depression during 1 year of British Journal of Psychiatry The National Pharmaceuticals Strategy: Rest in peace, revive or renew? - Apr 13, 2009 While the Common Drug Review recommended that the provinces not provide coverage for escitalopram (Cipralex) in November 2008, Ontario's Committee to CMAJ 룬드벡, ì•„ì?¼ëžœë“œ 엘란사 ì?¸ìˆ˜ì„¤â€¦ì„±ì‚¬ëŠ” 미지수 - Mar 31, 2009 ...다른 거래ë?„ 다ê°?ì ?으로 ì§„í–‰í•˜ê³ ìžˆë‹¤. ê·¸ ì?´ìœ 는 2012ë…„ 거대 품목ì?¸ ë ‰ì‚¬í”„ë¡œ(Lexapro: escitalopram)ì?˜ 특허 만료로 ë°œìƒ?ë? 매출 ê°?소를 보충하기 위해서다. 메디포뉴스 Advancell y Nobera unen su I+D en sÃndrome de mano-pie - Mar 29, 2009 Forest Laboratories ha recibido el visto bueno de la agencia estadounidense FDA para la ampliación de las indicaciones de Lexapro (escitalopram) para el Correo Farmacéutico í˜ˆì••ê°•í•˜ì œ 등 ì?˜ì•½í’ˆ 120ê°œ 15ì?¼ë¶€í„° ì‹ ê·œ 보험등재 - Apr 5, 2009 ...ì?´ë°–ì—? 종근당ì?˜ ‘ì—?ìŠ¤ì‹œíƒˆì •(escitalopram oxalate)’ 등 ì •ì‹ ì‹ ê²½ìš©ì œ 24개와 ì¤‘ì™¸ì œì•½ì?˜ â€˜ì¤‘ì™¸ì‹ ì•½í?´ë¦¬ì†Œë¥´ë² ì?´íЏ80ì ?안액(polysorbate80)’ 등 ì•ˆê³¼ìš©ì œ 1ê°œ, 헬스코리아뉴스 Rischio di emorragia gastroenterica con gli SSRI e SRNI - Mar 28, 2009 95% CI 1,5-5,7) e sertralina (OR 2,3; IC 95%1,0-5,1) riportavano il rischio più alto, seguiti da citalopram o escitalopram (OR: 2.0; IC 95%: 1,2-3,2). Pillole.org تتعرق Ø±Ø§ØØ§Øª اليدين بمجرد الشعور بالخوÙ?ØŒ Ù?ما تشخيص هذه Ø§Ù„ØØ§Ù„ة؟ - Apr 7, 2009 المثالي، هنالك أدوية مضادة لقلق المخاوÙ? Ø£Ù?ضلها عقار يعرÙ? تجاريًا باسم (سبرالكس Cipralex) ويعرÙ? علميًا باسم (استالوبرام Escitalopram)ØŒ أنا لستÙ? متأكدًا الشبكة الإسلامية Brand Names/Synonyms: Escitalopram is also known by the following brand names and/or synonymsEscitalopram; Escitalopram Oxalate; Escitalopram [Inn]; Lexapro Drug Category: Escitalopram is categorized under the following by the FDA: Antidepressive Agents, Second-Generation; Serotonin Uptake Inhibitors; ATC:N06AB10 Dosage Forms: TABLET Absorption: The absolute bioavailability of citalopram is about 80% relative to an intravenous dose Interactions: -->Interactions for Escitalopram: CNS Drugs - Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs. Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended. Monoamine Oxidase Inhibitors (MAOIs) - See Contraindications and Warnings. Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.) Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding. Thus, patients should be cautioned about the use of such drugs concurrently with LEXAPRO. Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. The clinical significance of these findings is unknown. Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered. Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised. Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated. Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered. Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam. Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram. Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram. CYP3A4 and -2C19 Inhibitors - In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance. Drugs Metabolized by Cytochrome P4502D6 - In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6. Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate. Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of ECT and escitalopram. Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered. Chemical IUPAC Name: 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |